Navigation Links
European Society for Medical Oncology and European CanCer Organization join forces
Date:4/9/2008

Lugano, Switzerland and Brussels, Belgium, 9 April 2008: The European Society for Medical Oncology (ESMO) and ECCO - the European CanCer Organisation have united forces to host a co-branded biennial multidisciplinary partnership meeting that will provide the best and most updated scientific data for everyone working in cancer and will also strengthen initiatives aimed at providing all cancer patients with equal access to high-quality cancer care.

The ECCO Congress, which takes place every two years, will become a joint ECCO-ESMO congress, and its scientific committee will be chaired both by ECCO and ESMO. The first congress will be 20-24 September 2009 in Berlin, with subsequent joint congresses being held biennially in the uneven-numbered years.

In the intervening even-numbered years between the ECCO-ESMO congresses, ESMO will continue to hold its own ESMO Congress. In 2008, the 33rd ESMO Congress will take place as planned, 12-16 September, in Stockholm, Sweden.

In addition, ESMOs Board of Directors unanimously voted on 4 April to become a founding member of the new ECCO organisation, composed of European cancer societies, and as a result, ESMO will have a seat on the ECCO Board of Directors. The ECCO Board unanimously accepted the proposal two weeks ago.

ECCO President, Professor Alexander M.M. Eggermont, said he was delighted. ESMO and ECCO have been discussing this for some time now, and we firmly believe that joining forces in this way will benefit all our member organisations, European cancer professionals and, most importantly, cancer patients.

With so much happening in Europe affecting advances in oncology, we need to work together when interacting with European policymakers and industry, so that they take notice, understand and act on our messages. ECCOs mission is to uphold the right of all cancer patients to the best possible treatment and care and to promote interaction between all organisations involved in cancer research, education, treatment and care at the European level. Together with ESMO, I am confident that we will be able to achieve this goal.

ESMO President, Professor Jos Baselga agreed, and added: This uniting of the landscape of European oncology is the result of an agreement on common goals combined with a strong spirit of goodwill and collaboration on all sides. In becoming a founding member of ECCO, we are convinced we will strengthen our ability to represent European oncologists and patients. ESMO is a community of professionals who share the common goal of providing the best possible care for all cancer patients a mission which is in total harmony with ECCOs objectives.

This is a win-win situation for ESMO, ECCO and all of our patients. I am looking forward to liaising closely with Professor Eggermont, not only in supporting medical oncology and cancer treatment by multidisciplinary teams, but also in working towards enhancing European conferences as attractive settings to present research done in Europe and worldwide. Looking ahead, we will combine our efforts to make the 2009 ECCO 15 34th ESMO Congress the best and biggest European cancer congress yet.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
2. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
3. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
4. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
5. Gene expression differences between Europeans and Africans affect response to drugs, infections
6. Space sentinels: New tools in space to improve European environment and security policies
7. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
8. Specialty European Pharma launches plenaxis in Germany
9. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
10. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
11. European Neuroscience and Society Network tackles neurosocieties head-on
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... With ProGlass Prism users now have the ability to simulate ... over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, ... ProGlass Prism users are given the tools and effects to generate a fractal ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating ... Me Beyond What You See” body image mannequin art competition. Selected from 15 submissions ... and the winner revealed at the 31st annual iaedp Symposium, March 22 – 26 ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning sunscreen ... Fondo of Marin. For the second year in a row, cyclists will stay ... “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
(Date:2/23/2017)... ... Markets has announced the addition of the "Global Antifungal Drugs Market ... offering. The Global Antifungal Drugs Market is poised to ... reach approximately $12.8 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
Breaking Medicine Technology: